Plant Name: Ginkgo semen
Taxonomic Information:
Plant ID: NPO16472
Plant Latin Name: Ginkgo semen
Taxonomy Genus: Ginkgo
Taxonomy Family: Ginkgoaceae
Plant External Links:
NCBI TaxonomyDB:
n.a.
Plant-of-the-World-Online:
n.a.
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| OPRD1; NPSR1; | |
| ADRA2B; | |
| ALPL; TDP1; TERT; PGD; ALOX12; HSD17B2; HSD17B10; NOX4; TNKS; TNKS2; POLB; | |
| ACHE; | |
| BCL2; | |
| TRPV1; | |
| MET; FLT3; CDK1; PIM1; AXL; KDR; IGF1R; AURKB; | |
| CA2; CA12; CA7; CA4; | |
| TYR; MAOA; | |
| AHR; TP53; NFKB1; | |
| DNMT1; | |
| ABCB1; | |
| SLCO1B1; | |
| LMNA; FABP4; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| ATP-binding cassette | ABCB1 | P-glycoprotein 1 | P08183 | CHEMBL4302 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| DNA methyltransferase | DNMT1 | DNA (cytosine-5)-methyltransferase 1 | P26358 | CHEMBL1993 |
| Enzyme_unclassified | TERT | Telomerase reverse transcriptase | O14746 | CHEMBL2916 |
| Enzyme_unclassified | PGD | 6-phosphogluconate dehydrogenase | P52209 | CHEMBL3404 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | TNKS | Tankyrase-1 | O95271 | CHEMBL6164 |
| Enzyme_unclassified | TNKS2 | Tankyrase-2 | Q9H2K2 | CHEMBL6154 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Enzyme_unclassified | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P05186 | CHEMBL5979 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Miscellaneous ion channel | BCL2 | Apoptosis regulator Bcl-2 | P10415 | CHEMBL4860 |
| Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
| Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
| Peptide receptor (family A GPCR) | OPRD1 | Delta opioid receptor | P41143 | CHEMBL236 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
| Small molecule receptor (family A GPCR) | ADRA2B | Alpha-2b adrenergic receptor | P18089 | CHEMBL1942 |
| Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Transient receptor potential channel | TRPV1 | Vanilloid receptor | Q8NER1 | CHEMBL4794 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 4.426E-09 | 9.638E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C9 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 2.854E-08 | 3.882E-05 | CA12, CA2, CA4, CA7 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 4.917E-08 | 4.656E-05 | CYP1A1, CYP1A2, CYP1B1, CYP2C9, NOX4 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.239E-07 | 8.535E-05 | CYP1A1, CYP1A2, CYP1B1, CYP2C9 |
| BP | GO:0009987; cellular process | GO:0043066; negative regulation of apoptotic process | 2.317E-07 | 1.294E-04 | ALOX12, AURKB, AXL, BCL2, CDK1, IGF1R, KDR, LMNA, NFKB1, PIM1, TERT, TP53 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.190E-06 | 4.800E-04 | CA12, CA2, CA4, CA7 |
| BP | GO:0051179; localization | GO:2001225; regulation of chloride transport | 1.220E-06 | 4.829E-04 | ABCB1, CA2, CA7 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 2.708E-06 | 9.361E-04 | CA12, CA2, CA4, CA7 |
| BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 3.360E-06 | 1.060E-03 | BCL2, LMNA, OPRD1, TERT, TP53 |
| BP | GO:0051179; localization | GO:0070198; protein localization to chromosome, telomeric region | 4.589E-06 | 1.384E-03 | TERT, TNKS, TNKS2 |
| BP | GO:0050896; response to stimulus | GO:0010332; response to gamma radiation | 6.208E-06 | 1.711E-03 | BCL2, NOX4, POLB, TP53 |
| BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 6.344E-06 | 1.727E-03 | BCL2, CA2, CA7, KDR, NPSR1, TRPV1 |
| BP | GO:0065007; biological regulation | GO:1904355; positive regulation of telomere capping | 6.837E-06 | 1.783E-03 | AURKB, TNKS, TNKS2 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 9.293E-06 | 2.248E-03 | CYP1A1, CYP1A2, CYP1B1, CYP2C9, NOX4 |
| BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 1.131E-05 | 2.593E-03 | ALPL, CYP1A1, CYP1B1, FLT3, NFKB1, NOX4, TRPV1 |
| BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 1.329E-05 | 2.888E-03 | CYP1A1, POLB, TP53 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.450E-05 | 3.066E-03 | CA2, CA7 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 1.764E-05 | 3.624E-03 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.764E-05 | 3.624E-03 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 2.734E-05 | 4.921E-03 | ALOX12, CYP1A1, CYP1A2, CYP1B1, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0070213; protein auto-ADP-ribosylation | 2.896E-05 | 5.016E-03 | TNKS, TNKS2 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 2.896E-05 | 5.016E-03 | CYP1A1, CYP1A2 |
| BP | GO:0009987; cellular process | GO:2000045; regulation of G1/S transition of mitotic cell cycle | 2.902E-05 | 5.016E-03 | BCL2, CDK1, CYP1A1, TERT, TP53 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 2.896E-05 | 5.016E-03 | CYP1A2, CYP2C9 |
| BP | GO:0050896; response to stimulus | GO:0033273; response to vitamin | 3.282E-05 | 5.497E-03 | ALPL, CYP1A1, TP53, TYR |
| BP | GO:0008152; metabolic process | GO:2000377; regulation of reactive oxygen species metabolic process | 3.554E-05 | 5.733E-03 | BCL2, CYP1B1, NOX4, TP53, TRPV1 |
| BP | GO:0051179; localization | GO:0051050; positive regulation of transport | 3.962E-05 | 6.162E-03 | ABCB1, ACHE, AXL, BCL2, CA2, CDK1, NPSR1, TERT, TP53, TRPV1 |
| BP | GO:0009987; cellular process | GO:1902533; positive regulation of intracellular signal transduction | 4.438E-05 | 6.665E-03 | ADRA2B, AXL, BCL2, CDK1, CYP1B1, FLT3, KDR, MET, NOX4, TP53 |
| BP | GO:0050896; response to stimulus | GO:0009611; response to wounding | 4.676E-05 | 6.974E-03 | ACHE, BCL2, CDK1, CYP1A1, TP53 |
| BP | GO:0008152; metabolic process | GO:0018108; peptidyl-tyrosine phosphorylation | 5.612E-05 | 7.988E-03 | AXL, FLT3, IGF1R, KDR, MET |
| BP | GO:0065007; biological regulation | GO:0032212; positive regulation of telomere maintenance via telomerase | 5.860E-05 | 8.232E-03 | AURKB, TNKS, TNKS2 |
| BP | GO:0040011; locomotion | GO:0014911; positive regulation of smooth muscle cell migration | 6.970E-05 | 9.369E-03 | BCL2, NOX4, TERT |
| BP | GO:0008152; metabolic process | GO:0046777; protein autophosphorylation | 7.194E-05 | 9.586E-03 | AURKB, FLT3, IGF1R, KDR, PIM1 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 7.220E-05 | 9.586E-03 | CYP1A2, CYP2C9 |
| MF | GO:0005488; binding | GO:0001221; transcription cofactor binding | 7.574E-05 | 9.995E-03 | AHR, TERT, TP53 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 1.988E-07 | 1.352E-05 | DNMT1, ABCB1, PIM1, BCL2, CYP1B1, TP53, MET, NFKB1 |
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 4.319E-08 | 5.873E-06 | CA12, CA2, CA4, CA7 |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 1.600E-06 | 7.252E-05 | MAOA, CYP1A2, CYP1A1, CYP1B1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 3.969E-06 | 1.349E-04 | HSD17B2, CYP1A1, CYP1B1, IGF1R |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 7.221E-06 | 1.964E-04 | CYP1A2, HSD17B2, CYP1A1, CYP1B1 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 1.810E-05 | 4.102E-04 | CYP2C9, CYP1A2, CYP1A1, CYP1B1 |
| 09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 3.960E-05 | 6.129E-04 | BCL2, TP53, NFKB1, IGF1R |
| Unclassified | Unclassified | hsa01100 | Metabolic pathways | 4.507E-05 | 6.129E-04 | CYP2C9, DNMT1, MAOA, HSD17B2, CYP1A2, CYP1A1, ALPL, ALOX12, PGD, TYR, HSD17B10 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 8.419E-05 | 1.041E-03 | KDR, BCL2, TP53, MET, NFKB1, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 2.868E-05 | 5.571E-04 | CYP2C9, CYP1A2, CYP1A1, CYP1B1 |
| 09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 4.075E-05 | 6.129E-04 | FLT3, TP53, MET, NFKB1, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 1.930E-04 | 2.019E-03 | FLT3, BCL2, MET, TP53, NFKB1, IGF1R |
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04210 | Apoptosis | 2.296E-04 | 2.231E-03 | LMNA, BCL2, TP53, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04071 | Sphingolipid signaling pathway | 1.269E-04 | 1.439E-03 | OPRD1, BCL2, TP53, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 2.498E-04 | 2.265E-03 | FLT3, PIM1, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 4.029E-04 | 3.223E-03 | FLT3, TP53, MET |
| 09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 4.778E-04 | 3.249E-03 | TP53, MET, IGF1R |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 3.685E-04 | 3.132E-03 | CYP2C9, CYP1A2, CYP1A1 |
| 09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 9.329E-04 | 5.263E-03 | KDR, TP53, MET, IGF1R |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 4.393E-04 | 3.249E-03 | CYP2C9, MAOA, CYP1A2 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05169 | Epstein-Barr virus infection | 9.159E-04 | 5.263E-03 | BCL2, CDK1, TP53, NFKB1 |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04510 | Focal adhesion | 9.159E-04 | 5.263E-03 | KDR, BCL2, MET, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05203 | Viral carcinogenesis | 9.675E-04 | 5.263E-03 | POLB, CDK1, TP53, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05222 | Small cell lung cancer | 8.366E-04 | 5.263E-03 | BCL2, TP53, NFKB1 |
| 09150 Organismal Systems | 09154 Digestive system | hsa04976 | Bile secretion | 4.778E-04 | 3.249E-03 | SLCO1B1, ABCB1, CA2 |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 1.332E-03 | 6.391E-03 | PIM1, BCL2, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 1.410E-03 | 6.391E-03 | KDR, MET, NFKB1, IGF1R |
| 09150 Organismal Systems | 09149 Aging | hsa04211 | Longevity regulating pathway - mammal | 1.083E-03 | 5.591E-03 | TP53, NFKB1, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 1.410E-03 | 6.391E-03 | BCL2, NFKB1, IGF1R |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05166 | HTLV-I infection | 2.249E-03 | 8.996E-03 | POLB, TERT, TP53, NFKB1 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 1.792E-03 | 7.618E-03 | CYP2C9, MAOA, ALOX12 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04722 | Neurotrophin signaling pathway | 2.182E-03 | 8.994E-03 | BCL2, TP53, NFKB1 |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00350 | Tyrosine metabolism | 2.568E-03 | 9.979E-03 | MAOA, TYR |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 1.767E-03 | 7.618E-03 | CYP2C9, CYP1A2 |
| 09150 Organismal Systems | 09155 Excretory system | hsa04964 | Proximal tubule bicarbonate reclamation | 1.110E-03 | 5.591E-03 | CA2, CA4 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | OPRD1; TYR; |
| G00-G99: Diseases of the nervous system G00-G99 | Acute migraine | G43 | OPRD1; TRPV1; |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; TERT; FLT3; DNMT1; TP53; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Acute or chronic pain | R52, G89 | TRPV1; |
| NA: NA | Acute nonspecific diarrhea | NA | OPRD1; |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
| C00-D49: Neoplasms | Soft tissue sarcoma | C00-D49 | DNMT1; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MET; AURKB; IGF1R; KDR; FLT3; TP53; ABCB1; |
| C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; TERT; AHR; BCL2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Musculoskeletal pain | R52, G89 | TRPV1; |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; MAOA; OPRD1; |
| A00-B99: Certain infectious and parasitic diseases | Anthelmintic | B89 | ALPL; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; FLT3; TP53; |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3; ALPL; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
| G00-G99: Diseases of the nervous system G00-G99 | Amyotrophic lateral sclerosis | G12.2 | BCL2; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
| C00-D49: Neoplasms | Melanoma | C43 | TERT; KDR; TYR; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; MAOA; |
| C00-D49: Neoplasms | Overactive bladder disorder | C67, N32.81 | OPRD1; TRPV1; |
| C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | ADRA2B; MAOA; OPRD1; |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
| A00-B99: Certain infectious and parasitic diseases | Postherpetic neuralgia | B02.2, G44.847, G53.0 | TRPV1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Premature ejaculation | F52.4 | OPRD1; |
| C00-D49: Neoplasms | Renal cancer | C64 | KDR; |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | TERT; |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
| NA: NA | Edema | NA | CA2; |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | ADRA2B; MAOA; TRPV1; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cough | R05 | OPRD1; TRPV1; |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | DNMT1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA; TYR; |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9; ABCB1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | TRPV1; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53; |
| C00-D49: Neoplasms | Tumors | C00-D48 | TERT; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA; |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ABCB1; |
| NA: NA | Upper abdominal bloating | NA | ACHE; |
| N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | OPRD1; TRPV1; |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA; |
| N00-N99: Diseases of the genitourinary system | Bladder disease | N30-N32 | OPRD1; |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR; |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TERT; KDR; TP53; |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53; |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
| C00-D49: Neoplasms | Breast cancer | C50 | CDK1; IGF1R; TERT; KDR; FLT3; BCL2; |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; OPRD1; |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
| K00-K95: Diseases of the digestive system | Gastroesophageal reflux disease | K21 | TRPV1; |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Genetic disease | Q00-Q99 | ALPL; |
| K00-K95: Diseases of the digestive system | Diarrhea-predominant IBS | K58.0 | OPRD1; |
| C00-D49: Neoplasms | Cancer | C00-C96 | PIM1; MET; CDK1; IGF1R; KDR; NFKB1; FLT3; ACHE; DNMT1; TP53; ABCB1; BCL2; |
| H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | TERT; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; ACHE; CA2; |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | TRPV1; |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
| C00-D49: Neoplasms | Glioma | C71 | KDR; |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; |
| NA: NA | GIST | NA | FLT3; |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
| C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; TERT; KDR; |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | DNMT1; TP53; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; BCL2; |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
| NA: NA | Esophagus sensitivity | NA | TRPV1; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | TERT; KDR; ABCB1; |
| I00-I99: Diseases of the circulatory system | Ischemic heart diseases | I20-I25 | OPRD1; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | BCL2; |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
| NA: NA | Chronic diarrhea associated with inflammatory bowel disease | NA | OPRD1; |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; MAOA; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | TERT; KDR; FLT3; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | CDK1; IGF1R; ACHE; OPRD1; TRPV1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; TP53; |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Moderate-to-severe pain | R52, G89 | OPRD1; |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | BCL2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pathological pain | R52, G89 | TRPV1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; DNMT1; |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R; |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
| C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
| C00-D49: Neoplasms | CLL | NA | FLT3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | TRPV1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; BCL2; |
| C00-D49: Neoplasms | Prostate cancer | C61 | TERT; FLT3; BCL2; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
| NA: NA | HIV infections | NA | AHR; |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53; |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1; |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
| C00-D49: Neoplasms | Advanced melanoma | C43 | BCL2; |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; AXL; DNMT1; ABCB1; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
